Market Overview

UPDATE: JP Morgan Raises PT to $31 on Pfizer Following Q4 Results, Guidance

Related PFE
Will The New Pfizer Be A Winner? SunTrust Analyst Thinks So, Upgrades Stock
EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Biotechs Weaken, But These Names Have Bullish Charts (Investor's Business Daily)

JP Morgan maintained Pfizer, Inc. (NYSE: PFE) with an Overweight and raised the price target from $29.00 to $31.00.

JP Morgan said, "While there were no major surprises in the guidance, management did confirm that they expect share repurchase to reach mid-teens billions of dollars range this year. More importantly, management's comments on the call reinforced our view that a larger split-up of the company remains a real possibility longer-term, something we believe would be a clear upside event for Pfizer shares. Despite the move the stock has had, we continue to see a number of drivers for further upside ranging from new product flow, to additional capital return and accretive bolt-on acquisitions."

Pfizer closed at $27.70 on Tuesday.

Latest Ratings for PFE

Nov 2015SunTrust Robinson HumphreyUpgradesReduceNeutral
Nov 2015Argus ResearchMaintainsBuy
Oct 2015Cowen & CompanyUpgradesMarket PerformOutperform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters